Needham & Company LLC reaffirmed their hold rating on shares of Omeros (NASDAQ:OMER) in a research report report published on Wednesday, AnalystRatings.com reports.
A number of other research analysts also recently commented on OMER. Maxim Group set a $32.00 price objective on Omeros and gave the stock a buy rating in a research note on Friday, August 9th. HC Wainwright reiterated a buy rating and issued a $34.00 target price (down from $35.00) on shares of Omeros in a research note on Monday, December 2nd. ValuEngine cut Omeros from a hold rating to a sell rating in a research note on Thursday, November 14th. Zacks Investment Research downgraded shares of Omeros from a hold rating to a sell rating in a report on Saturday, November 16th. Finally, Wedbush restated a hold rating and set a $18.00 price target on shares of Omeros in a research report on Friday, November 15th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $24.00.
Shares of OMER stock opened at $13.16 on Wednesday. The company has a market cap of $654.68 million, a P/E ratio of -5.93 and a beta of 2.65. The business has a 50 day moving average of $14.71 and a two-hundred day moving average of $16.40. Omeros has a 52 week low of $10.30 and a 52 week high of $20.92.
Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08. The company had revenue of $29.86 million for the quarter, compared to analyst estimates of $27.19 million. The firm’s revenue for the quarter was up 547.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.81) earnings per share. As a group, analysts anticipate that Omeros will post -1.13 earnings per share for the current fiscal year.
In related news, Director Thomas J. Cable sold 5,000 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $15.12, for a total value of $75,600.00. Following the completion of the transaction, the director now directly owns 35,067 shares of the company’s stock, valued at approximately $530,213.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas J. Cable sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $13.16, for a total value of $131,600.00. 12.80% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in OMER. Nuveen Asset Management LLC bought a new position in shares of Omeros in the second quarter worth $3,221,000. Chicago Equity Partners LLC acquired a new position in shares of Omeros during the second quarter valued at $1,094,000. Stifel Financial Corp increased its holdings in shares of Omeros by 9.4% during the third quarter. Stifel Financial Corp now owns 740,959 shares of the biopharmaceutical company’s stock valued at $12,092,000 after purchasing an additional 63,891 shares during the period. Ingalls & Snyder LLC raised its stake in shares of Omeros by 1.2% during the third quarter. Ingalls & Snyder LLC now owns 5,023,755 shares of the biopharmaceutical company’s stock valued at $82,038,000 after purchasing an additional 58,198 shares in the last quarter. Finally, Virtus ETF Advisers LLC bought a new stake in shares of Omeros during the second quarter valued at about $784,000. 52.19% of the stock is currently owned by hedge funds and other institutional investors.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Recommended Story: What is an investor looking for in an SEC filing?
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.